Mark J. Casey, J.D., serves as the Executive Vice President, Chief Legal Officer, and Corporate Secretary at Novavax, Inc., a biotechnology company focused on developing innovative vaccines. With a robust background in the legal and corporate sectors, Casey brings extensive experience to his role at Novavax. He joined the company in 2018 and has since been instrumental in navigating the complex legal landscape surrounding the development and commercialization of vaccines. Prior to his tenure at Novavax, Casey held several high-profile positions that honed his expertise in corporate governance and compliance. He previously served as the Senior Vice President, General Counsel, and Corporate Secretary at Emergent BioSolutions, another leading biopharmaceutical company. During his time there, he played a key role in guiding the company through significant growth and regulatory challenges. Casey's career also includes a stint as a partner at the law firm of Hogan Lovells, where he specialized in corporate transactions and securities law. His educational background includes a Juris Doctor from the University of Maryland School of Law and a Bachelor of Arts from the University of Notre Dame. In his current role at Novavax, Casey is responsible for overseeing all legal matters, including intellectual property, litigation, and corporate governance. His leadership has been vital in ensuring that Novavax adheres to the highest standards of legal and ethical conduct as it advances its vaccine candidates through clinical trials and toward market approval. Under his guidance, Novavax has successfully managed numerous regulatory hurdles and strategic partnerships, positioning the company for future success in the competitive biopharmaceutical industry. Casey's strategic vision and legal acumen continue to be invaluable assets to Novavax as it strives to bring life-saving vaccines to the global market.